微小 RNA 作为一种新型工具在肝脂质失调和脂肪肝疾病诊断中的应用。
MicroRNAs as a Novel Tool in the Diagnosis of Liver Lipid Dysregulation and Fatty Liver Disease.
机构信息
Shenzhen University Medical Center, Shenzhen University Health Science Center, Shenzhen 518060, China.
Department of Biology, Guangdong Pharmaceutical University, Guangzhou 510006, China.
出版信息
Molecules. 2019 Jan 9;24(2):230. doi: 10.3390/molecules24020230.
Abstract
In recent years, metabolic disorder, especially fatty liver disease, has been considered a major challenge to global health. The attention of researchers focused on expanding knowledge of the regulation mechanism behind these diseases and towards the new diagnostics tools and treatments. The pathophysiology of the fatty liver disease is undoubtedly complex. Abnormal hepatic lipid accumulation is a major symptom of most metabolic diseases. Therefore, the identification of novel regulation factors of lipid metabolism is important and meaningful. As a new diagnostic tool, the function of microRNAs during fatty liver disease has recently come into notice in biological research. Accumulating evidence supports the influence of miRNAs in lipid metabolism. In this review, we discuss the potential role of miRNAs in liver lipid metabolism and the pathogenesis of fatty liver disease.
摘要
近年来，代谢紊乱，尤其是脂肪肝疾病，被认为是对全球健康的主要挑战。研究人员的注意力集中在扩展这些疾病背后的调控机制的知识上，并针对新的诊断工具和治疗方法。脂肪肝疾病的病理生理学无疑是复杂的。异常的肝脂质积累是大多数代谢疾病的主要症状。因此，鉴定脂质代谢的新型调控因子是重要且有意义的。作为一种新的诊断工具，微小 RNA 在脂肪肝疾病中的功能在最近的生物学研究中受到了关注。越来越多的证据支持 miRNA 在脂质代谢中的影响。在这篇综述中，我们讨论了 miRNA 在肝脂质代谢和脂肪肝疾病发病机制中的潜在作用。
相似文献
1
MicroRNAs as a Novel Tool in the Diagnosis of Liver Lipid Dysregulation and Fatty Liver Disease.
Molecules. 2019 Jan 9;24(2):230. doi: 10.3390/molecules24020230.
2
miRNAs in non-alcoholic fatty liver disease.
Front Med. 2016 Dec;10(4):389-396. doi: 10.1007/s11684-016-0468-5. Epub 2016 Dec 23.
3
Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease.
Biochim Biophys Acta Mol Cell Biol Lipids. 2017 Sep;1862(9):869-882. doi: 10.1016/j.bbalip.2017.05.001. Epub 2017 May 5.
4
Critical Roles of microRNAs in the Pathogenesis of Fatty Liver: New Advances, Challenges, and Potential Directions.
Biochem Genet. 2018 Oct;56(5):423-449. doi: 10.1007/s10528-018-9870-9. Epub 2018 Jun 27.
5
'Micro-managers' of hepatic lipid metabolism and NAFLD.
Wiley Interdiscip Rev RNA. 2015 Sep-Oct;6(5):581-93. doi: 10.1002/wrna.1295. Epub 2015 Jul 21.
6
Role of microRNAs in alcohol-induced liver disorders and non-alcoholic fatty liver disease.
World J Gastroenterol. 2018 Sep 28;24(36):4104-4118. doi: 10.3748/wjg.v24.i36.4104.
7
MicroRNA-185 regulates expression of lipid metabolism genes and improves insulin sensitivity in mice with non-alcoholic fatty liver disease.
World J Gastroenterol. 2014 Dec 21;20(47):17914-23. doi: 10.3748/wjg.v20.i47.17914.
8
miRNA Regulation of Glucose and Lipid Metabolism in Relation to Diabetes and Non-alcoholic Fatty Liver Disease.
Adv Exp Med Biol. 2019;1134:129-148. doi: 10.1007/978-3-030-12668-1_7.
9
MicroRNAs as biomarkers and regulators of nonalcoholic fatty liver disease.
J Dig Dis. 2016 Nov;17(11):708-715. doi: 10.1111/1751-2980.12408.
10
miR-26a Potentially Contributes to the Regulation of Fatty Acid and Sterol Metabolism In Vitro Human HepG2 Cell Model of Nonalcoholic Fatty Liver Disease.
Oxid Med Cell Longev. 2018 Sep 30;2018:8515343. doi: 10.1155/2018/8515343. eCollection 2018.
引用本文的文献
1
A Comparison of Novel Serum Markers of Liver Health in Adolescents With Metabolic Dysfunction-Associated Steatotic Liver Disease.
J Cell Mol Med. 2025 Aug;29(16):e70817. doi: 10.1111/jcmm.70817.
2
The Role of miRNAs and Epigenetic Factors in Non-Alcoholic Fatty Liver Disease - a Systematic Review.
Curr Health Sci J. 2025 Jan-Mar;51(1):37-52. doi: 10.12865/CHSJ.51.01.04. Epub 2025 Mar 31.
3
From fatty liver to fibrosis: the impact of miRNAs on NAFLD and NASH.
Funct Integr Genomics. 2025 Jan 31;25(1):30. doi: 10.1007/s10142-025-01544-x.
4
The contribution of genetics and epigenetics to MAFLD susceptibility.
Hepatol Int. 2024 Oct;18(Suppl 2):848-860. doi: 10.1007/s12072-024-10667-5. Epub 2024 Apr 25.
5
Rosavin Ameliorates Hepatic Inflammation and Fibrosis in the NASH Rat Model via Targeting Hepatic Cell Death.
Int J Mol Sci. 2022 Sep 5;23(17):10148. doi: 10.3390/ijms231710148.
6
MiR-199b-5p Promotes Gastric Cancer Progression by Regulating HHIP Expression.
Front Oncol. 2021 Aug 31;11:728393. doi: 10.3389/fonc.2021.728393. eCollection 2021.
7
Targeting miRNA by Natural Products: A Novel Therapeutic Approach for Nonalcoholic Fatty Liver.
Evid Based Complement Alternat Med. 2021 Aug 13;2021:6641031. doi: 10.1155/2021/6641031. eCollection 2021.
8
The Target MicroRNAs and Potential Underlying Mechanisms of Yiqi-Bushen-Tiaozhi Recipe against-Non-Alcoholic Steatohepatitis.
Front Pharmacol. 2020 Nov 12;11:529553. doi: 10.3389/fphar.2020.529553. eCollection 2020.
9
miRNA Dysregulation in the Development of Non-Alcoholic Fatty Liver Disease and the Related Disorders Type 2 Diabetes Mellitus and Cardiovascular Disease.
Front Med (Lausanne). 2020 Sep 22;7:527059. doi: 10.3389/fmed.2020.527059. eCollection 2020.
10
Pediatric Non-Alcoholic Fatty Liver Disease: Nutritional Origins and Potential Molecular Mechanisms.
Nutrients. 2020 Oct 16;12(10):3166. doi: 10.3390/nu12103166.
本文引用的文献
1
Application of Real-Time Cell Electronic Analysis System in Modern Pharmaceutical Evaluation and Analysis.
Molecules. 2018 Dec 11;23(12):3280. doi: 10.3390/molecules23123280.
2
Enhanced Liver Regeneration After Partial Hepatectomy in Sterol Regulatory Element-Binding Protein (SREBP)-1c-Null Mice is Associated with Increased Hepatocellular Cholesterol Availability.
Cell Physiol Biochem. 2018;47(2):784-799. doi: 10.1159/000490030. Epub 2018 May 22.
3
Comprehensive epigenetic landscape of rheumatoid arthritis fibroblast-like synoviocytes.
Nat Commun. 2018 May 15;9(1):1921. doi: 10.1038/s41467-018-04310-9.
4
Identification by shape-based virtual screening and evaluation of new tyrosinase inhibitors.
PeerJ. 2018 Jan 26;6:e4206. doi: 10.7717/peerj.4206. eCollection 2018.
5
RGD Peptide-Based Target Drug Delivery of Doxorubicin Nanomedicine.
Drug Dev Res. 2017 Sep;78(6):283-291. doi: 10.1002/ddr.21399. Epub 2017 Aug 16.
6
Functional interaction of the two-pore domain potassium channel TASK-1 and caveolin-3.
Biochim Biophys Acta Mol Cell Res. 2017 Oct;1864(10):1537-1544. doi: 10.1016/j.bbamcr.2017.06.016. Epub 2017 Jun 23.
7
Redox-triggered mitoxantrone prodrug micelles for overcoming multidrug-resistant breast cancer.
J Drug Target. 2018 Jan;26(1):75-85. doi: 10.1080/1061186X.2017.1339195. Epub 2017 Jun 18.
8
Orally delivered polycurcumin responsive to bacterial reduction for targeted therapy of inflammatory bowel disease.
Drug Deliv. 2017 Nov;24(1):233-242. doi: 10.1080/10717544.2016.1245367.
9
Discovery of novel inhibitors disrupting HIF-1/von Hippel-Lindau interaction through shape-based screening and cascade docking.
PeerJ. 2016 Dec 15;4:e2757. doi: 10.7717/peerj.2757. eCollection 2016.
10
Circulating microRNAs: Possible role as non-invasive diagnostic biomarkers in liver disease.
Clin Res Hepatol Gastroenterol. 2017 Sep;41(4):370-377. doi: 10.1016/j.clinre.2016.11.001. Epub 2016 Dec 9.
Zotero 插件